JLE

Hépato-Gastro & Oncologie Digestive

MENU

Évolution du traitement des métastases hépatiques colorectales : vers une définition de l’épargne parenchymateuse Volume 25, numéro 3, Mars 2018

  • [1] Van C.E., Cervantes A., Adam R. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386-1422.
  • [2] Evrard S, Poston G, Kissmeyer-Nielsen P, et al. Combined ablation and resection (CARe) as an effective parenchymal sparing treatment for extensive colorectal liver metastases. PLoS One 2014 ; 9 : e114404.
  • [3] de Haas R.J., Wicherts D.A., Flores E. R1 resection by necessity for colorectal liver metastases : is it still a contraindication to surgery? Ann Surg. 2008;248:626-637.
  • [4] Gold JS, Are C, Kornprat P, et al. Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: Trends in treatment over time in 440 patients. Ann Surg 2008 ; 247 : 109-117.
  • [5] Kopetz S., Chang G.J., Overman M.J. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677-3683.
  • [6] Folprecht G., Gruenberger T., Bechstein W.O. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab : the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38-47.
  • [7] Gruenberger T., Bridgewater J., Chau I. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015;26:702-708.
  • [8] van Vledder M.G., de Jong M.C., Pawlik T.M. Disappearing colorectal liver metastases after chemotherapy : Should we be concerned? J Gastrointest Surg. 2010;14:1691-1700.
  • [9] Brouquet A, Abdalla EK, Kopetz S, et al. High survival rate after two-stage resection of advanced colorectal liver metastases : response-based selection and complete resection define outcome. J Clin Oncol 2011 ; 29 : 1083-1090.
  • [10] Cauchy F., Aussilhou B., Dokmak S. Reappraisal of the risks and benefits of major liver resection in patients with initially unresectable colorectal liver metastases. Ann Surg. 2012;256:746-752.
  • [11] Wanis K.N., Buac S., Linecker M. Patient Survival After Simultaneous ALPPS and Colorectal Resection. World J Surg. 2016.
  • [12] Truant S., Baillet C., Deshorgue A.C. Drop of Total Liver Function in the Inter-stages of the New Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy Technique : Analysis of the “Auxiliary Liver” by HIDA Scintigraphy. Ann Surg. 2016;263:e33-e34.
  • [13] Moris D., Tsilimigras D.I., Chakedis J. Liver transplantation for unresectable colorectal liver metastases : A systematic review. J Surg Oncol. 2017;116:288-297.
  • [14] Evrard S, Rivoire M, Arnaud J et al. Unresectable colorectal cancer liver metastases treated by intraoperative radiofrequency ablation with or without resection. Br J Surg 2012 ; 99 : 558-565.
  • [15] Ruers T, Punt C, van Coevorden F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases : a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 2012 ; 23 : 2619-2626.
  • [16] Imai K, Allard MA, Castro BC, et al. Long-term outcomes of radiofrequency ablation combined with hepatectomy compared with hepatectomy alone for colorectal liver metastases. Br J Surg 2017 ; 104 : 570-579.
  • [17] Abbott D.E., Sohn V.Y., Hanseman D. Cost-effectiveness of simultaneous resection and RFA versus 2-stage hepatectomy for bilobar colorectal liver metastases. J Surg Oncol. 2014;109:516-520.
  • [18] Abdalla E.K., Vauthey J.N., Ellis L.M. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Data validation in an economic evaluation of surgery for colon cancer. Ann Surg. 2004;239:818-825.
  • [19] Curley S.A. Radiofrequency ablation versus resection for resectable colorectal liver metastases : time for a randomized trial? Ann Surg Oncol. 2008;15:11-13.
  • [20] Memeo R., de B.V., Adam R. Parenchymal-sparing hepatectomies (PSH) for bilobar colorectal liver metastases are associated with a lower morbidity and similar oncological results : a propensity score matching analysis. HPB (Oxford). 2016;18:781-790.
  • [21] Hosokawa I, Allard MA, Mirza DF, et al. Outcomes of parenchyma-preserving hepatectomy and right hepatectomy for solitary small colorectal liver metastasis : A LiverMetSurvey study. Surgery 2017 ; 162 : 223-232.
  • [22] Mise Y., Aloia T.A., Brudvik K.W. Parenchymal-sparing Hepatectomy in Colorectal Liver Metastasis Improves Salvageability and Survival. Ann Surg. 2016;263:146-152.
  • [23] Torzilli G, Cimino M, Procopio F, et al. Conservative hepatectomy for tumors involving the middle hepatic vein and segment 1: the liver tunnel. Ann Surg Oncol 2014 ; 21 : 2699.
  • [24] Desjardin M, Desolneux G, Brouste V, et al. Parenchymal sparing surgery for colorectal liver metastases: The need for a common definition. Eur J Surg Oncol 2017 ; 43 : 2285-2291.
  • [25] Evrard S. In favour of One-Stage Strategy (OSS). Eur J Surg Oncol. 2015;41:1568-1569.
  • [26] Adam R., Wicherts D.A., de Haas R.J. Patients with initially unresectable colorectal liver metastases : is there a possibility of cure? J Clin Oncol. 2009;27:1829-1835.